tiprankstipranks
Kiniksa Pharmaceuticals Ltd. Class A (KNSA)
NASDAQ:KNSA
US Market
KNSA
Kiniksa Pharmaceuticals
RESEARCH TOOLSreports
Want to see KNSA full AI Analyst Report?

Kiniksa Pharmaceuticals (KNSA) Stock Forecast & Price Target

565 Followers
See the Price Targets and Ratings of:

KNSA Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Kiniksa
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KNSA Stock 12 Month Forecast

Average Price Target

$64.00
▲(42.54% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Kiniksa Pharmaceuticals in the last 3 months. The average price target is $64.00 with a high forecast of $72.00 and a low forecast of $57.00. The average price target represents a 42.54% change from the last price of $44.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","73":"$73","37.75":"$37.8","49.5":"$49.5","61.25":"$61.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$64.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$57.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,37.75,49.5,61.25,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.27,56.55692307692308,57.84384615384616,59.13076923076923,60.417692307692306,61.70461538461539,62.99153846153846,64.27846153846154,65.56538461538462,66.85230769230769,68.13923076923076,69.42615384615385,70.71307692307693,{"y":72,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.27,55.941538461538464,56.613076923076925,57.284615384615385,57.956153846153846,58.62769230769231,59.299230769230775,59.970769230769235,60.642307692307696,61.31384615384616,61.98538461538462,62.65692307692308,63.32846153846154,{"y":64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.27,55.403076923076924,55.53615384615385,55.66923076923077,55.80230769230769,55.93538461538462,56.06846153846154,56.20153846153846,56.33461538461538,56.46769230769231,56.60076923076923,56.73384615384615,56.86692307692308,{"y":57,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.27,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$72.00Average Price Target$64.00Lowest Price Target$57.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on KNSA
Anupam Rama
J.P. Morgan
J.P. Morgan
$68→$72
Buy
60.36%
Upside
Reiterated
05/04/26
Analysts Are Bullish on These Healthcare Stocks: Kiniksa Pharmaceuticals (KNSA), Kymera Therapeutics (KYMR)
Canaccord Genuity Analyst forecast on KNSA
Edward Nash
Canaccord Genuity
Canaccord Genuity
$62→$64
Buy
42.54%
Upside
Assigned
04/29/26
Canaccord Genuity Reaffirms Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)
Wedbush Analyst forecast on KNSA
David Nierengarten
Wedbush
Wedbush
$58→$59
Buy
31.40%
Upside
Reiterated
04/29/26
Wedbush Remains a Buy on Kiniksa Pharmaceuticals (KNSA)
Wells Fargo Analyst forecast on KNSA
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$53→$57
Buy
26.95%
Upside
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Kiniksa Pharmaceuticals (NASDAQ: KNSA) and Incyte (NASDAQ: INCY)
Citi Analyst forecast on KNSA
Geoff Meacham
Citi
Citi
$50→$60
Buy
33.63%
Upside
Reiterated
04/29/26
Kiniksa price target raised to $60 from $50 at CitiKiniksa price target raised to $60 from $50 at Citi
TD Cowen Analyst forecast on KNSA
Nicholas Lorusso
TD Cowen
TD Cowen
$60→$65
Buy
44.77%
Upside
Reiterated
04/28/26
Lorusso Lifts Price Target to $65 and Reiterates Buy on Strong Arcalyst Momentum and Upside Potential
Jefferies Analyst forecast on KNSA
Roger Song
Jefferies
Jefferies
$58→$71
Buy
58.13%
Upside
Reiterated
04/28/26
Kiniksa price target raised to $71 from $58 at JefferiesKiniksa price target raised to $71 from $58 at Jefferies
Goldman Sachs Analyst forecast on KNSA
Paul Choi
Goldman Sachs
Goldman Sachs
$45→$55
Buy
22.49%
Upside
Reiterated
10/29/25
Goldman Sachs Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on KNSA
Anupam Rama
J.P. Morgan
J.P. Morgan
$68→$72
Buy
60.36%
Upside
Reiterated
05/04/26
Analysts Are Bullish on These Healthcare Stocks: Kiniksa Pharmaceuticals (KNSA), Kymera Therapeutics (KYMR)
Canaccord Genuity Analyst forecast on KNSA
Edward Nash
Canaccord Genuity
Canaccord Genuity
$62→$64
Buy
42.54%
Upside
Assigned
04/29/26
Canaccord Genuity Reaffirms Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)
Wedbush Analyst forecast on KNSA
David Nierengarten
Wedbush
Wedbush
$58→$59
Buy
31.40%
Upside
Reiterated
04/29/26
Wedbush Remains a Buy on Kiniksa Pharmaceuticals (KNSA)
Wells Fargo Analyst forecast on KNSA
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$53→$57
Buy
26.95%
Upside
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (NASDAQ: MIRM), Kiniksa Pharmaceuticals (NASDAQ: KNSA) and Incyte (NASDAQ: INCY)
Citi Analyst forecast on KNSA
Geoff Meacham
Citi
Citi
$50→$60
Buy
33.63%
Upside
Reiterated
04/29/26
Kiniksa price target raised to $60 from $50 at CitiKiniksa price target raised to $60 from $50 at Citi
TD Cowen Analyst forecast on KNSA
Nicholas Lorusso
TD Cowen
TD Cowen
$60→$65
Buy
44.77%
Upside
Reiterated
04/28/26
Lorusso Lifts Price Target to $65 and Reiterates Buy on Strong Arcalyst Momentum and Upside Potential
Jefferies Analyst forecast on KNSA
Roger Song
Jefferies
Jefferies
$58→$71
Buy
58.13%
Upside
Reiterated
04/28/26
Kiniksa price target raised to $71 from $58 at JefferiesKiniksa price target raised to $71 from $58 at Jefferies
Goldman Sachs Analyst forecast on KNSA
Paul Choi
Goldman Sachs
Goldman Sachs
$45→$55
Buy
22.49%
Upside
Reiterated
10/29/25
Goldman Sachs Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kiniksa Pharmaceuticals

3 Months
Eva Fortea VerdejoWells Fargo
Success Rate
10/11 ratings generated profit
91%
Average Return
+20.65%
Copying Eva Fortea Verdejo's trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +20.65% per trade.
1 Year
Eva Fortea VerdejoWells Fargo
Success Rate
11/11 ratings generated profit
100%
Average Return
+67.38%
Copying Eva Fortea Verdejo's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +67.38% per trade.
2 Years
Eva Fortea VerdejoWells Fargo
Success Rate
11/11 ratings generated profit
100%
Average Return
+120.95%
Copying Eva Fortea Verdejo's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +120.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KNSA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
7
11
10
14
10
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
11
10
14
10
In the current month, KNSA has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KNSA average Analyst price target in the past 3 months is 64.00.
Each month's total comprises the sum of three months' worth of ratings.

KNSA Financial Forecast

KNSA Earnings Forecast

Next quarter’s earnings estimate for KNSA is $0.30 with a range of $0.25 to $0.38. The previous quarter’s EPS was $0.27. KNSA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KNSA has Performed in-line its overall industry.
Next quarter’s earnings estimate for KNSA is $0.30 with a range of $0.25 to $0.38. The previous quarter’s EPS was $0.27. KNSA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KNSA has Performed in-line its overall industry.

KNSA Sales Forecast

Next quarter’s sales forecast for KNSA is $226.56M with a range of $219.52M to $230.00M. The previous quarter’s sales results were $214.27M. KNSA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KNSA has Performed in-line its overall industry.
Next quarter’s sales forecast for KNSA is $226.56M with a range of $219.52M to $230.00M. The previous quarter’s sales results were $214.27M. KNSA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KNSA has Performed in-line its overall industry.

KNSA Stock Forecast FAQ

What is KNSA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kiniksa Pharmaceuticals Ltd. Class A’s 12-month average price target is 64.00.
    What is KNSA’s upside potential, based on the analysts’ average price target?
    Kiniksa Pharmaceuticals Ltd. Class A has 42.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KNSA a Buy, Sell or Hold?
          Kiniksa Pharmaceuticals Ltd. Class A has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Kiniksa Pharmaceuticals Ltd. Class A’s price target?
            The average price target for Kiniksa Pharmaceuticals Ltd. Class A is 64.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $72.00 ,the lowest forecast is $57.00. The average price target represents 42.54% Increase from the current price of $44.9.
              What do analysts say about Kiniksa Pharmaceuticals Ltd. Class A?
              Kiniksa Pharmaceuticals Ltd. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of KNSA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.